Travoprost

From Wikipedia, the free encyclopedia
Travoprost
Travoprost structure.svg
Clinical data
Trade namesTravatan, Izba, others
AHFS/Drugs.comMonograph
MedlinePlusa602027
License data
Pregnancy
category
Routes of
administration		Topical eye drops
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only)
  • US: ℞-only
  • EU: Rx-only [2]
  • In general: ℞ (Prescription only)
Pharmacokinetic data
MetabolismActivation by ester hydrolysis, deactivation by beta oxidation, OH-oxidation, double bond reduction
Onset of action2 hours
Elimination half-life1.5 hours (in aqueous fluid)
45 minutes (terminal)
Duration of action≥ 24 hours
ExcretionMainly via kidney
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.207.141 Edit this at Wikidata
Chemical and physical data
FormulaC26H35F3O6
Molar mass500.555 g·mol−1
3D model (JSmol)
 ☒NcheckY (what is this?)  

Travoprost, sold under the brand name Travatan among others, is a medication used to treat high pressure inside the eye including glaucoma.[3] Specifically it is used for open angle glaucoma when other agents are not sufficient.[4][3] It is used as an eye drop.[3] Effects generally occur within two hours.[3]

Common side effects include red eyes, blurry vision, eye pain, dry eyes, and change in color of the eyes.[3][4] Other significant side effects may include cataracts.[4] Use during pregnancy or breastfeeding is generally not recommended.[4] It is a prostaglandin analog and works by increasing the outflow of aqueous fluid from the eyes.[3]

Travoprost was approved for medical use in the United States and in the European Union in 2001.[3][2] It is available as a generic medication in the United Kingdom.[4] In 2017, it was the 212th most commonly prescribed medication in the United States, with more than two million prescriptions.[5][6]

Medical uses[]

Travoprost is used to treat high pressure inside the eye including glaucoma.[3] Specifically it is used for open angle glaucoma when other agents are not sufficient.[4][3]

Side effects[]

One 2.5 ml dropperette of Travatan

Possible side effects are:[7]

  • blurred vision
  • eyelid redness
  • permanent darkening of eyelashes
  • eye discomfort
  • permanent darkening of the iris to brown (heterochromia)
  • burning sensation during use
  • thickening of the eyelashes
  • inflammation of the prostate gland, restricting urine flow (BPH)[citation needed]

Research suggests that wiping the eye with an absorbent pad after the administration of eye drops can result in shorter eyelashes and a lesser chance of hyperpigmentation in the eyelid, compared to not wiping off excess fluid.[8]

Pharmacology[]

Mechanism of action[]

It is a synthetic prostaglandin analog (or more specifically, an analog of prostaglandin F2α)[9][10] that works by increasing the outflow of aqueous fluid from the eyes.[11]

Like other analogs of prostaglandin F2α such as tafluprost and latanoprost, travoprost is an ester prodrug of the free acid, which acts as an agonist at the prostaglandin F receptor, increasing outflow of aqueous fluid from the eye and thus lowering intraocular pressure.[7]

Pharmacokinetics[]

Travoprost is absorbed through the cornea, where it is hydrolysed to the free travoprost acid. Highest concentrations of the acid in the eye are reached one to two hours after application, and its half-life in the aqueous fluid is 1.5 hours. Once it reaches the bloodstream, it is quickly metabolised, so that concentrations in the system do not exceed 25 pg/ml (compared to 20 ng/ml in the eye, which is higher by nearly a factor of 1000).[7]

Metabolites are formed by beta oxidation of the acidic chain (compare Tafluprost#Pharmacokinetics), oxidation of the OH-group in the other side chain, and reduction of the double bond next to this OH-group. Travoprost acid and its metabolites are mainly excreted via the kidney[7] with a terminal half-life of 45 minutes.[12]

Various products have undergone clinical trial to deliver continuous steady release. OTX-TP (Ocular Therapeutix) completed phase III trial showing superior results to placebo out to 12 weeks.[13]

References[]

  1. ^ "Travoprost ophthalmic Use During Pregnancy". Drugs.com. 8 October 2019. Retrieved 16 May 2020.
  2. ^ Jump up to: a b "Travatan EPAR". European Medicines Agency (EMA). Retrieved 3 January 2021.
  3. ^ Jump up to: a b c d e f g h i "Travoprost Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 26 March 2019.
  4. ^ Jump up to: a b c d e f British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 1152. ISBN 9780857113382.
  5. ^ "The Top 300 of 2020". ClinCalc. Retrieved 11 April 2020.
  6. ^ "Travoprost - Drug Usage Statistics". ClinCalc. Retrieved 11 April 2020.
  7. ^ Jump up to: a b c d Haberfeld, H, ed. (2015). Austria-Codex (in German). Vienna: Österreichischer Apothekerverlag. Travatan 40 Mikrogramm/ml Augentropfen.
  8. ^ Xu L, Wang X, Wu M (February 2017). "Topical medication instillation techniques for glaucoma". The Cochrane Database of Systematic Reviews. 2: CD010520. doi:10.1002/14651858.CD010520.pub2. PMC 5419432. PMID 28218404.
  9. ^ Alcon Laboratories, Inc. (September 2011). "Travatan - travoprost solution". DailyMed. Bethesda, MD: U.S. National Library of Medicine. Retrieved 2011-09-30.
  10. ^ Alcon Laboratories, Inc. (September 2011). "Travatan Z (travoprost) solution". DailyMed. Bethesda, MD: U.S. National Library of Medicine. Retrieved 2011-09-30.
  11. ^ AHFS Consumer Medication Information (2011-01-01). "Travoprost Ophthalmic". MedlinePlus. Bethesda, MD: U.S. National Library of Medicine. Retrieved 2011-09-30.
  12. ^ Drugs.com: Travoprost Monograph.
  13. ^ "Deliver Us from Noncompliance".

External links[]

  • "Travoprost". Drug Information Portal. U.S. National Library of Medicine.
Retrieved from ""